![François Conquet](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
François Conquet
Fondateur chez Prexton Therapeutics SA
Profil
François Conquet is the founder of Prexton Therapeutics SA, which he founded in 2012 and where he holds the title of Chief Executive Officer & Director.
He is currently the Chief Executive Officer & Co-Managing Director at Exciva GmbH.
Postes actifs de François Conquet
Sociétés | Poste | Début |
---|---|---|
Prexton Therapeutics SA
![]() Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Fondateur | 01/01/2012 |
Exciva GmbH
![]() Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | Directeur Général | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Prexton Therapeutics SA
![]() Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Health Technology |
Exciva GmbH
![]() Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | Commercial Services |